Advances in hepatitis C therapies

Abstract

Introduction: The recent development of new direct acting antivirals constitutes a clinical revolution in the field of hepatitis C therapy. Different drugs with direct antiviral effects and very high potency have been developed, changing the current scenario and prognosis of hepatitis C-related liver disease. This review aims to clarify the current stage of the different antiviral strategies in patients with chronic hepatitis C infection by analyzing the specific efficacy of each combination.

Areas covered: Data have been extracted from the most important published clinical trials, cumulative real-world experience reports and data from the most relevant studies presented in the last international meetings (European and American International Liver Congresses). In addition, data from the recently updated international guidelines have also been included.

Expert opinion: Although there are many differences in health-care budgets among countries in the world which will surely compromise drug availability and treatment decisions, this review aims to give a general and brief recommendation to help treating physicians to choose the best option to treat hepatitis C.

Keywords:

• direct acting antivirals
• hepatitis C
• interferon-free combinations

Declaration of interest

Z Mariño has acted as an advisor for BMS and has received speaker fees from Janssen and Gilead. X Forns is an advisor for Gilead, Janssen, and Abbvie; he has also received unrestricted grant support from Janssen. S Lens is an advisor for Gilead and Janssen and has received speaker fees from Gilead, Janssen, and Abbvie. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Notes

This box summarizes key points contained in the article.